Priority 20 from the Rare Musculoskeletal Diseases in Adulthood PSP
| UNCERTAINTY: How does drug treatment need to change as people with rare metabolic bone disorders get older? (JLA PSP Priority 20) | |
|---|---|
| Overall ranking | 20 |
| JLA question ID | 0076/20 |
| Explanatory note | Not available for this PSP |
| Evidence |
None identified |
| Health Research Classification System category | Musculoskeletal |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | OI: are there any benefits to treating adults with OI with bisphosphonates? If so, who should be treated? ~ Will my treatment need adjusting as I get older? ~ Is there a consensus on whether it is effective for XLH patients to take phosphates at all ages? It seems that opinion varies. |
| Submitted by | Individual survey submissions categorised by Health or Social Care Professionals, Organisations representing people with rare musculoskeletal diseases, people with rare musculoskeletal diseases, relatives/carers/friends, Other. For full details of the type of submitter for each individual question, please see the spreadsheet of data held on the JLA website. |
| PSP information | |
|---|---|
| PSP unique ID | 0076 |
| PSP name | Rare Musculoskeletal Diseases in Adulthood |
| Total number of uncertainties identified by this PSP. | 39 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 18 June 2018 |